NRIX | Nurix Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	19.66 - 20.61
52 Week Range	7.65 - 29.56
Beta	2.03
Implied Volatility	113.15%
IV Rank	27.31%
Day's Volume	2,484,664
Average Volume	902,720
Shares Outstanding	70,836,300
Market Cap	1,404,683,829
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-07-24

Valuation
Profitability
Growth
Health
P/E Ratio	-6.84
Forward P/E Ratio	N/A
EPS	-2.90
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	284
Country	USA
Website	NRIX

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

NRIX's peers: AGIO, ARVN, BCAB, BHVN, CCCC, CDXS, CLLS, FHTX, GLUE, HUMA, IKNA, IMAB, IMUX, KYMR, KZIA, KZR, STTK, ELYM, PRLD, RLAY, STOK, PLRX, BDTX, NKTX, LYEL, GBIO, SANA, QSI, RPTX, RVMD, SEER, TNGX, VOR

*Chart delayed

Analyzing fundamentals for NRIX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see NRIX Fundamentals page.

Watching at NRIX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on NRIX Technicals page.